Regentis Biomaterials, a company focused on developing proprietary hydrogels for tissue regeneration, has raised $10 million in its latest round of funding from new investors Royal DSM through its venturing subsidiary, Crossroad Fund, Medica Venture Partners, SCPVitalife and Technion Investment Opportunities Fund.

The United States biomaterials market shows significant potential for growth in the future, according to a report from iData research.

BioMimetic Therapeutics, a Franklin, Tenn.-based medical device company, reported a net loss of $6.1 million during the first quarter of 2012.

San Francisco-based SpineGuard has expanded its United States sales and established four areas to support demand from independent distributors and market its PediGuard family of products.

Kensey Nash reported $22.2 million in revenue and $16.1 million in net sales for the third quarter of the 2012 fiscal year.

Exactech reported net income of $3.3 million during the first quarter of 2012, a slight increase over the same period in 2011.

DJO Global reported net sales of $278.9 million and net loss of $29 million during the first quarter of 2012.

Zimmer reported $1.4 billion in first quarter net sales, a 2.2 percent increase over the same period last year.

Orthofix's first quarter net sales were reported at $143.1 million, a 3 percent growth over the same period last year, with spine products net sales up 3 percent to $75 million and orthopedics up 1 percent to $41 million.

A new CEO has taken the reigns at Johnson & Johnson, and he plans major changes for the company, according to a New York Times report.